DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B Stock

Certificat

DE000ME9P1S5

Real-time Bid/Ask 11:37:10 2024-07-03 EDT
120.43 EUR / 120.47 EUR -2.46% Intraday chart for DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B
Current month-0.55%
1 month+4.68%
Date Price Change
24-07-03 122.2 -1.09%
24-07-02 123.5 -0.98%
24-07-01 124.7 +0.43%
24-06-28 124.2 -0.02%
24-06-27 124.2 -0.22%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 09:03 am

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME9P1S
ISINDE000ME9P1S5
Date issued 2024-03-06
Cap 140 $
Last trading day 2024-09-20
Maturity 2024-09-20 (79 Days)
Parity 1 : 1
Emission price 112.3
Emission volume N/A
Payment day 2024-09-27
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 5.226 %
Sideways yield 5.532 %
Sideways yield pa 25.56 %
Outperformance point 147.7 $
Break even 130.48 €
Highest since issue 124.7
Lowest since issue 107.2
Spread 0.02
Spread %0.02%
Distance Cap -2.235 $
Distance Cap %-1.62%
Max. earning 8.816
Max. earning % 7.298 %

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
993.5 DKK
Average target price
952.2 DKK
Spread / Average Target
-4.16%
Consensus